Literature DB >> 15558835

Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection.

Guy W Neff1, Christopher B O'Brien, Jose Nery, Norah J Shire, Seigo Nishida, Julia delaGarza, Marzia Montalbano, Kamran Safdar, Phillip Ruiz, Eric Rideman, Jose A Gascon, Andreas G Tzakis, Juan Madariaga, Steven M Rudich.   

Abstract

Hepatitis C virus (HCV) is becoming the most common indication for liver retransplantation (ReLTx). This study was a retrospective review of the medical records of liver transplant patients at our institution to determine factors that would identify the best candidates for ReLTx resulting from allograft failure because of HCV recurrence. The patients were divided into 2 groups on the basis of indication for initial liver transplant. Group 1 included ReLTx patients whose initial indication for LTx was HCV. Group 2 included patients who received ReLTx who did not have a history of HCV. We defined chronic allograft dysfunction (AD) as patients with persistent jaundice (> 30 days) beginning 6 months after primary liver transplant in the absence of other reasons. HCV was the primary indication for initial orthotopic liver transplantation (OLT) in 491/1114 patients (44%) from July 1996 to February 2004. The number of patients with AD undergoing ReLTx in Groups 1 and 2 was 22 and 12, respectively. The overall patient and allograft survival at 1 year was 50% and 75% in Groups 1 and 2, respectively (P = .04). The rates of primary nonfunction and technical problems after ReLTx were not different between the groups. However, the incidence of recurrent AD was higher in Group 1 at 32% versus 17% in Group 2 (P = .04). Important factors that predicted a successful ReLTx included physical condition at the time of ReLTx (P = .002) and Child-Turcotte-Pugh score (P = .008). In conclusion, HCV is associated with an increased incidence of chronic graft destruction with a negative effect on long-term results after ReLTx. The optimum candidate for ReLTx is a patient who can maintain normal physical activity. As the allograft shortage continues, the optimal use of cadaveric livers continues to be of primary importance. The use of deceased donor livers in patients with allograft failure caused by HCV remains a highly controversial issue.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15558835     DOI: 10.1002/lt.20301

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

Review 1.  A systematic review of provider knowledge of hepatitis C: is it enough for a complex disease?

Authors:  Susan L Zickmund; Kyle E Brown; Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

2.  Significant influence of the primary liver disease on the outcomes of hepatic retransplantation.

Authors:  A Qasim; B M Zaman; J Geoghegan; D Maguire; O Traynor; J Hegarty; P A McCormick
Journal:  Ir J Med Sci       Date:  2008-11-04       Impact factor: 1.568

Review 3.  Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.

Authors:  Jérôme Dumortier; Olivier Boillot; Jean-Yves Scoazec
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 4.  Management of hepatitis C infection after liver transplantation.

Authors:  Mazen Alsatie; Naga Chalasani; Paul Y Kwo
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Retransplantation for graft failure in chronic hepatitis C infection: a good use of a scarce resource?

Authors:  Ian A Rowe; Kerri M Barber; Rhiannon Birch; Elinor Curnow; James M Neuberger
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

6.  Liver transplantation and hepatitis C.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara
Journal:  Int J Hepatol       Date:  2012-07-26

Review 7.  Recurrence of hepatitis C after liver transplantation.

Authors:  Carmen Vinaixa; Angel Rubín; Victoria Aguilera; Marina Berenguer
Journal:  Ann Gastroenterol       Date:  2013
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.